Thus, simultaneously inhibiting both Akt and ERK pathways rather than a single pathway would be a more efficient approach to ameliorate drug response and suppress tumor growth (He et al., 2019; Yu et al., 2019). The gene discussed is AKT1; the disease is neoplasm.